Home › Compare › HLBYL vs ABBV
HLBYL yields 440527.92% · ABBV yields 3.06%● Live data
📍 HLBYL pulled ahead of the other in Year 1
Combined, HLBYL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HLBYL + ABBV for your $10,000?
Heron Lake BioEnergy, LLC produces and sells ethanol and co-products, and non-edible corn oil in the United States. It operates in two segments, Ethanol Production and Natural Gas Pipeline. The company offers fuel-grade ethanol, which is used as an octane enhancer in fuels; as an oxygenated fuel additive that could reduce ozone and carbon monoxide vehicle emissions; as a non-petroleum-based gasoline substitute; and as a renewable fuel to displace consumption of imported oil. It also provides distillers' grains, an animal feed ingredient primarily marketed to the dairy and beef industries; crude corn oil, which is used principally as a biodiesel feedstock and as a supplement for animal feed; and corn syrup primarily used as a feed additive to moisten dry feed stuffs, such as hay. In addition, the company operates a natural gas pipeline that provides natural gas to its ethanol production facility and other customers. It distributes and markets its products through third party marketers. The company was formerly known as Generation II, LLC and changed its name to Heron Lake BioEnergy, LLC in June 2004. The company was founded in 2001 and is headquartered in Heron Lake, Minnesota. As of January 29, 2020, Heron Lake BioEnergy, LLC operates as a subsidiary of Granite Falls Energy, LLC.
Full HLBYL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.